Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

Although the primary endpoint was not met, axitinib was associated with significantly increased PFS and ORR for patients with previously-treated, advanced extrapancreatic neuroendocrine tumors.

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Sandostatin (octreotide acetate) is a prescription drug used to treat acromegaly and other conditions. Sandostatin can cause side effects that range from mild to serious. Examples include diarrhea and ...

Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe ...

Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.

Product: All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) with the lot numbers noted below. Issue: Health products – Product quality What to do: If ...